WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leisure Acquisition Corp. , a special purpose acquisition company, in connection with the Company’s proposed merger with Ensysce Biosciences, Inc. (“Ensysce”), a privately held clinical-stage drug company.  Under the terms of the merger agreement, Leisure will acquire Ensyce through a reverse merger that will result in Ensysce becoming a public company traded on the NASDAQ.  The transaction is valued at approximately $207 million.

Or please contact:
Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771

stockinfo@weisslawllp.com

WeissLaw LLP is investigating whether Leisure’s board acted in the best interest of Leisure’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Ensysce, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to Leisure’s public shareholders. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

See Campaign: http://weisslawllp.com
Contact Information:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Tags:
, Wire, Legal Newswire, United States, English